Business Wire

CD Capital Natural Resources Fund III Monetization of Filo Mining stake for C$158.3 Million

Share

CD Capital Natural Resources Fund III ("CD Capital”) successfully monetizes its equity investment in Filo Mining for a total consideration of C$158.3 million.

Filo Mining is a Canadian exploration and development company focused on advancing its 100% owned Filo del Sol copper-gold-silver deposit located in Chile's Region III and adjacent San Juan Province, Argentina. CD took a strategic stake in the company back in 2020 enabling an expansion program of drilling to define deeper sulphide mineralisation. The Filo del Sol project has since been described as a high-sulphidation epithermal copper-gold-silver deposit associated with one or more large porphyry copper-gold systems with overlapping mineralizing events.

This drilling, undertaken over the past couple of years, has delivered some of the most spectacular mineralised intercepts of copper and gold the market has witnessed in decades. Recent drill results, such as the recent announcement of drill hole FSDH071 intersected 1,028.0m at 1.16% CuEq from a depth of 292m, including;172.0m at 2.14% CuEq from 408.0m and 237.5m at 1.49% CuEq from 776.0m, continue this success.

CD Capital was one of the early institutional investors to finance the drilling at Filo and the exploration success has been witnessed not only by the markets but also with Filo Mining attracting investment from BHP, who precipitated a C$100m strategic investment into Filo Mining in May 2022.

CD Capital is proud to have been an early institutional investor, alongside the Lundin Group, to support and finance the exploration and project development. The drilling is proving to be transformative for the company and has positioned it for future growth, confirming CD Capital's vision in supporting the leadership of the Lundin Group and the Filo del Sol project.

Founder & CEO of CD Capital, Carmel Daniele, noted the eventual monetization of the fund’s holding in Filo Mining, was part of the fund's normal course of business and mandate terms, delivering a substantial multiple of invested capital since acquisition. The project has more to deliver and CD looks forward to seeing this project flourish into a leading global copper and gold producer. "CD Capital is proud to have been involved in one of the largest copper discoveries in decades and personally has been one of the highlights of my career to see it come into fruition. It has been a truly spectacular investment for CD Capital Fund III’s investors and we are confident Filo’s journey to more success will continue. We look forward to the opportunity of partnering up on similar world-class projects led by top tier management teams with a strong proven track record, such as the Lundin Group, through the combination of our long-term patient institutional capital and our sector expertise to unlock value from exciting future projects in the pipeline.”

Chairman of the board of Filo Mining, Adam Lundin, commented, "We are appreciative for the support from CD Capital, who again believed in the vision of a Lundin Group entity in its early days. The equity participation alongside the family at the beginning of COVID in 2020 allowed us to continue to advance Filo del Sol into what is turning into truly a world class discovery. I would also like to extend a special thanks to CD Capital’s Founder & CEO, Carmel Daniele, for her continued valuable contributions as a Board member of Filo Mining. It has been an amazing journey and we will continue to unlock more value from this fantastic asset. We look forward to creating further value for CD Capital investors on current and future ventures within the Lundin Group."

About CD Capital Group

Over the past 15 years, London based CD Capital has launched three Private Equity funds, having raised circa US$1 billion in long-term patient capital, predominantly from leading North American institutional investors, including endowments and foundations, family offices and corporate pension funds. CD Capital develops world-class projects globally in precious metals, critical metals for greening the world, as well as fertilisers for global food security. CD Capital has a unique focus on partnering up with repeat management teams that have a strong track record in successfully developing projects in Latin America, such as Brazil, Peru, Argentina, Guatemala as well as Canada, Finland, Greenland and Australia.

CD Capital was founded in 2006 by Ms Daniele, who was one of the first in London to set up a dedicated fund focused on private mining assets and winning the prestigious Mines & Money Fund Manager of the Year award in 2008. Since establishing CD Capital, Ms Daniele has built a world-class investment technical team of industry insiders and has been an active sponsor and employer of women studying mining geology at Imperial College, London, resulting in a successful nomination to the 100 Women in Mining for 2022.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dominic Chapman
Chief Financial Officer
ir@cd-capital.com
+44 (0) 207 389 1450

Carmel Daniele
Founder, CIO & CEO
ir@cd-capital.com
+44 (0) 207 389 1450
www.cd-capital.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)22.10.2025 10:30:00 EEST | Press release

Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and the University Hospitals Birmingham NHS Foundation Trust, today announced new overall survival (OS) insights from the PROCLIPI (PROgnostic Cutaneous Lymphoma International Prognostic Index) Study aligning with previous findings that suggest mogamulizumab may offer meaningful OS benefit for patients living with mycosis fungoides (MF) and Sézary syndrome (SS), two rare conditions and subtypes of cutaneous T-cell lymphoma (CTCL).2 Key findings2: For patients with advanced-stage MF and SS (n=371), the median overall survival from the onset of treatment was higher for patients treated with mogamulizumab (n=72) at 64 months compared with those not receiving mogamulizumab (n=175) at 54 months (p<0.01). Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk

World First: H-UKR 0% Clinker Cement Obtains Technical Assessment (ATec) for Wind Turbine Foundations22.10.2025 09:00:00 EEST | Press release

Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative cold produced, clinker-free cements, today announces that it has obtained a Technical Assessment (ATec) validating the use of its H-UKR decarbonized cement for wind turbine foundations. This unprecedented recognition, a world first for a 0% clinker cement, certifies that the H-UKR solution meets the highest standards of sustainability, safety, and performance for particularly rigorous applications such as wind power. A strategic step towards new markets This certification marks another key milestone for Hoffmann Green, enabling it to further accelerate its growth in the renewable energy market from 2026 and beyond. Obtaining this ATec certification paves the way for new commercial opportunities in this sector, strengthening its insurability with project owners

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors22.10.2025 03:25:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China.* IBI363 is being evaluated in non-small cell lung and colorectal cancers and has shown potential efficacy in additional solid tumor types. IBI343 is being evaluated in gastric and pancreatic cancers. Takeda will also receive an exclusive option to license global rights outside of Greater China for IBI3001, an early-stage investigational medicine. “IBI363 and IBI343, two next-generation investigational medicines, have the potential to address critical treatment gaps for patients with a range of solid tumors,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “We are energized by the progress made by Innovent to date and look forward to collaborating to unlock the potential of t

YES Selected to Deliver Full Portfolio of Advanced Packaging Tools for Glass Panel AI and HPC Applications by a Leading AI Infrastructure Supplier21.10.2025 22:16:00 EEST | Press release

Yield Engineering Systems (YES), a leading provider of advanced process equipment for AI and high-performance computing (HPC) semiconductor applications, today announced that it has received multiple tool orders from a global leader in AI infrastructure solutions. The orders span YES’s portfolio of Dry and Wet process systems and will support panel-level manufacturing on glass substrates for next-generation data center and HPC packaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020459437/en/ YES VertaCure, VertaPrime, VeroFlex, TersOra, and SURE systems. The systems will be deployed in advanced packaging lines dedicated to hyperscale AI workloads, including training, inference, networking, and co-packaged optics. This award marks a significant milestone in the industry's shift toward glass-based 2.5D and 3D packaging as system performance, density, and thermal requirements escalate. YES will supply a full suite of s

Esri and UNFPA Extend Strategic Partnership to Support 2030 Census Round21.10.2025 22:09:00 EEST | Press release

Esri, the global leader in location intelligence, today announced the extension of its strategic partnership with the United Nations Population Fund (UNFPA) in support of the 2030 census round. Building on a successful collaboration during the 2020 census round, the partnership aims to embed geographic information system (GIS) technology into all phases of census work. By leveraging GIS, national statistics and census offices will gain access to more authoritative, location-enabled data and faster, more efficient methods of planning, collection, and dissemination. “National census projects can often involve mapping an entire country,” said Linda Peters, Esri global business development manager. “GIS is becoming crucial for every step of a census but deploying it is new to many national statistical offices. We are happy to provide the resources that can enable this large-scale feat of authoritative data collection and communication.” The integration of location intelligence into census

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye